General Information About Hepcvir L
Hepcvir-L is used to treat chronic hepatitis C virus genotype 1 in adults. Hepcvir-L is an antiviral drug that contains 2 active ingredients: 90mg of ledipasvir and 400mg of sofosbuvir. Ledipasvir, an inhibitor of the HCV NS5A protein, and sofosbuvir, an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, work together to stop the replication of hepatitis C virus genotype 1.
The recommended dosage of Hepcvir-L is 1 tablet taken once daily with or without food. This treatment regimen may vary if you have hepatitis or HIV-1 co-infection. If a dose is missed, take it as soon as you remember, unless it is already time for the next dose. Do not take a double dose to compensate for a missed dose.
Hepcvir-L follows the same contraindications for ribavirin. For example, patients with autoimmune hepatitis or hemoglobinopathies are not recommended to take this medication. Additionally, if you are allergic to ledipasvir, sofosbuvir or any of the other components in this formulation, do not use it.
Following treatment with Hepcvir-L, you may experience side effects such as:
More serious reactions may follow treatment with Hepcvir-L, such as:
Serious symptomatic bradycardia;
And skin rashes, usually accompanied by blisters.
Speak to your medical practitioner if any adverse reactions occur.
If you have underlying medical conditions, you may experience major health complications if Hepcvir-L is accidentally co-administered with unsuitable drugs. For example, when ledipasvir and sofosbuvir were administered concomitantly with amiodarone, there were documented post-marketing cases of symptomatic bradycardia and cardiac arrest, which required pacemaker intervention. Patients with underlying cardiac problems and/or advanced liver disease, or those who taking beta-blockers, may be at an increased risk of developing symptomatic bradycardia when they are co-administered with amiodarone. Consult a doctor before considering this medication.
Since this antiviral medication contains both ledipasvir and sofosbuvir, any drugs that interact with these 2 components can also interact with Hepcvir-L. These drugs may include:
Antacids (e.g. aluminum and magnesium hydroxide);
Antiarrhythmic agents (e.g. amiodarone, digoxin);
Anticonvulsants (e.g. carbamazepine, phenytoin);
Antimycobacterial agents (e.g. rifabutin, rifampin, rifapentine);
HMG-CoA reductase inhibitors (e.g. rosuvastatin);
Proton pump inhibitors (e.g. omeprazole);
And herbal supplements (e.g. St. John’s Wort).
Pregnancy & Lactation
There is currently no adequate research on the use of ledipasvir and sofosbuvir in pregnant women. There is also no clinical research regarding whether this drug is excreted in human breast milk. Therefore, it is best to consult a doctor if you are pregnant, planning to get pregnant, or breastfeeding to discuss your and your children’s safety.
Currently, there is no known antidote for ledipasvir and sofosbuvir overdoses. If you have accidentally overdosed on Hepcvir-L, you must be monitored by a doctor for any signs of toxicity. In order to avoid an overdose, do not take more than the recommended dose prescribed by your physician. If you do not feel as if your medication is working, discuss alternatives with your doctor.
Alternative Brand Names
Hepcvir-L is also known as Harvoni in the US and Canada
Reviews are only written by verified customers who have purchased this product.